RMD

+ Watchlist + Portfolio

ResMed Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $229.99
52-Week Range: $180.27 – $293.81
Market Cap: $32.95B
P/E (TTM): 22.11
EPS (TTM): 10.33
Dividend Yield: 1.14%

Advanced Metrics

Price/Book: 5.02
PEG Ratio: 1.34
Return on Equity: 24.27%
Return on Assets: 14.00%
Gross Margin: 61.62%
Operating Margin: 30.86%
Profit Margin: 26.95%
Current Ratio: 3.10
Debt/Equity: 0.13
Total Debt: $825.92M
Free Cash Flow: $939.25M
Revenue Growth: 8.60%
Earnings Growth: 2.40%
Enterprise Value: $32.31B

RMD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$3.58B	$4.22B	$4.69B	$5.15B
Cost of Revenue	$1.55B	$1.87B	$2.03B	$2.09B
Gross Profit	$2.02B	$2.36B	$2.66B	$3.05B
Research & Development	$253.57M	$287.64M	$307.52M	$331.28M
Selling, General & Admin	$737.51M	$874.00M	$917.14M	$991.02M
Operating Expenses	$1.02B	$1.20B	$1.27B	$1.37B
Operating Income	$1.00B	$1.15B	$1.38B	$1.69B
EBITDA	$1.18B	$1.35B	$1.60B	$1.92B
Pretax Income	$960.48M	$1.10B	$1.26B	$1.68B
Income Tax	$181.05M	$204.11M	$243.85M	$276.84M
Net Income	$779.44M	$897.56M	$1.02B	$1.40B
Diluted EPS	5.30	6.09	6.92	—
Diluted Shares	147.04M	147.46M	147.55M	—

RMD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$273.71M	$227.89M	$238.36M	$1.21B
Receivables	$575.95M	$704.91M	$875.46M	$990.67M
Inventory	$743.91M	$998.01M	$822.25M	$927.71M
Current Assets	$1.93B	$2.37B	$2.36B	$3.51B
Total Assets	$5.10B	$6.75B	$6.87B	$8.17B
Current Liabilities	$689.30M	$758.53M	$910.65M	$1.02B
Long-Term Debt	$765.33M	$1.43B	$697.31M	$658.39M
Total Debt	$917.55M	$1.58B	$873.93M	$851.81M
Total Liabilities	$1.74B	$2.62B	$2.01B	$2.21B
Retained Earnings	$3.61B	$4.25B	$4.99B	$6.08B
Shareholders' Equity	$3.36B	$4.13B	$4.86B	$5.97B
Working Capital	$1.24B	$1.61B	$1.45B	$2.49B
Net Debt	$501.53M	$1.21B	$468.85M	—

RMD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$351.15M	$693.30M	$1.40B	$1.75B
Capital Expenditure	-$156.04M	-$134.00M	-$114.86M	-$100.64M
Free Cash Flow	$195.11M	$559.30M	$1.29B	$1.65B
Depreciation & Amortisation	$193.84M	$197.56M	$216.21M	$235.81M
Stock-Based Compensation	$65.26M	$71.14M	$80.18M	$91.66M
Investing Cash Flow	-$229.92M	-$1.16B	-$269.78M	-$200.04M
Financing Cash Flow	-$128.36M	$422.87M	-$1.12B	-$606.25M
Dividends Paid	-$245.34M	-$258.28M	-$282.32M	-$310.88M
Share Repurchases	$0.00	$0.00	-$150.01M	-$300.02M
Net Change in Cash	-$7.13M	-$43.67M	$12.19M	$945.29M

RMD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$1.29B	$1.35B	$1.34B	$1.42B	$1.43B
Cost of Revenue	$525.33M	$527.92M	$514.76M	$544.08M	$540.43M
Gross Profit	$766.41M	$820.07M	$820.82M	$878.72M	$890.98M
Research & Development	$83.94M	$86.44M	$87.32M	$90.97M	$94.27M
Selling, General & Admin	$245.30M	$265.13M	$259.19M	$278.40M	$285.65M
Operating Expenses	$340.14M	$363.50M	$358.47M	$381.13M	$391.17M
Operating Income	$426.27M	$456.57M	$462.35M	$497.60M	$499.81M
EBITDA	$478.18M	$530.86M	$520.02M	$559.92M	$568.84M
Pretax Income	$417.69M	$458.05M	$446.79M	$496.15M	$502.31M
Income Tax	$52.65M	$78.35M	$98.26M	$103.56M	$103.58M
Net Income	$365.04M	$379.70M	$348.54M	$392.59M	$398.73M
Diluted EPS	2.48	2.58	2.37	2.68	2.74
Diluted Shares	147.22M	147.04M	146.90M	146.37M	145.72M

RMD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$932.71M	$1.21B	$1.38B	$1.42B	$1.66B
Receivables	$939.52M	$990.67M	$958.42M	$1.05B	$1.05B
Inventory	$862.64M	$927.71M	$945.81M	$922.04M	$911.88M
Current Assets	$3.21B	$3.51B	$3.63B	$3.82B	$4.06B
Total Assets	$7.57B	$8.17B	$8.31B	$8.50B	$8.78B
Current Liabilities	$940.52M	$1.02B	$1.26B	$1.25B	$1.35B
Long-Term Debt	$663.13M	$658.39M	$408.66M	$403.92M	$404.17M
Total Debt	$839.77M	$851.81M	$846.35M	$847.72M	$843.17M
Total Liabilities	$2.02B	$2.21B	$2.19B	$2.18B	$2.29B
Retained Earnings	$5.78B	$6.08B	$6.34B	$6.65B	$6.96B
Shareholders' Equity	$5.55B	$5.97B	$6.12B	$6.32B	$6.49B
Working Capital	$2.27B	$2.49B	$2.37B	$2.57B	$2.71B

RMD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$578.66M	$538.77M	$457.32M	$339.75M	$554.13M
Capital Expenditure	-$23.79M	-$33.78M	-$45.78M	-$34.55M	-$39.59M
Free Cash Flow	$554.87M	$504.99M	$411.54M	$305.19M	$514.54M
Depreciation & Amortisation	$51.91M	$74.29M	$57.67M	$62.33M	$69.03M
Stock-Based Compensation	$24.12M	$24.75M	$21.16M	$28.94M	$26.79M
Investing Cash Flow	-$31.79M	-$133.71M	-$52.58M	-$50.94M	-$58.03M
Financing Cash Flow	-$144.07M	-$163.89M	-$230.27M	-$258.35M	-$255.24M
Dividends Paid	-$77.70M	-$77.59M	-$87.75M	-$87.58M	-$87.24M
Share Repurchases	-$75.03M	-$100.01M	-$150.01M	-$175.01M	-$175.01M
Net Change in Cash	$402.80M	$241.17M	$174.47M	$30.45M	$240.86M

Market Snapshot

About

ResMed Inc. is a global medical equipment company that develops, manufactures, and distributes medical devices and cloud-based software for the treatment of sleep-disordered breathing and other respiratory conditions. The company is a leader in continuous positive airway pressure (CPAP) devices and digital health solutions for sleep apnea, COPD, and other chronic diseases. ResMed serves patients in over 140 countries through its innovative connected care platform.